Sector News

Struggling Endo's latest restructuring puts 90 staffers out of work

January 26, 2017
Life sciences

It hasn’t been a happy new year so far for Endo, which is starting 2017 the same way it closed out 2016: with layoffs.

The Dublin drugmaker has kicked off its latest phase of restructuring, which will claim 90 jobs and cost the company $15 million to $20 million, it said Thursday. The affected positions fall primarily within corporate functions and branded pharma R&D at the company’s Malvern, Pennsylvania, and Chestnut Ridge, New York, bases.

The expected results? $40 million to $50 million in pretax cost savings by the end of this year, the company said.

It’s the third round of recent layoffs for struggling Endo, which is looking to stage a comeback under new leadership. Last May, the company announced it would slash 740 jobs in Charlotte, North Carolina, and Huntsville, Alabama, in an effort to save money across its generics manufacturing network. And in December, it unveiled plans to sideline its once-core pain business, putting 375 sales reps and other staffers out of a job in the process.

This time around, the job cuts will “better align” the corporate functions and branded pharma R&D units with the recently edited generics and branded pharma divisions, Endo said in a statement. The bright side? These departments will be “the last of the organizations to be impacted,” CEO Paul Campanelli said in a statement.

Endo, like many of its specialty peers, has had a rough go of it lately. Last year, it hacked down its full-year guidance to well below Street forecasts, citing new market rivals, greater-than-expected generics price erosion and regulatory delays.

Since then, the company has bid some top execs farewell; in September, Campanelli, a former Par Pharmaceutical CEO, took the helm from Valeant vet Rajiv De Silva, and CFO Suketu Upadhyay made his own exit the following month.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

December 5, 2021

Catherine Mazzacco is leaving the position as President and CEO of LEO Pharma

Life sciences

After more than two years of leading LEO Pharma through a major transformation and a change of capital structure in a volatile environment during the global pandemic, the Board of Directors of LEO Pharma and President and CEO Catherine Mazzacco have jointly agreed that she will resign from her current role and leave the company on November 30, 2021.

December 5, 2021

Lonza and Bioqube Ventures to scale biologics and small molecules

Life sciences

Lonza and Bioqube Ventures, a European venture capital firm with a dual investment model including venture creation, have partnered to develop and manufacture biologics and small molecules. This is a five-year services agreement in which Lonza will provide advice and services to Bioqube Ventures’ portfolio companies.

December 5, 2021

UCB and Chiesi enter global license agreement for zampilimab a novel monoclonal antibody for fibrotic lung diseases

Life sciences

UCB has granted to Chiesi global exclusive rights to develop, manufacture and commercialize zampilimab, a monoclonal antibody targeting transglutaminase 2 (TG2), an enzyme associated in fibrotic diseases. UCB will receive upfront payment, future milestone payments and net sales royalties.

Send this to a friend